



## PRESS RELEASE

### **HRA Pharma Announces CEO Transition to Position Company for the Next Phase of Growth**

*François Vuillet to succeed Erin Gainer as CEO, bringing significant executive and operating experience. Erin Gainer joins Board of Directors as Non-Executive Director.*

**Paris, France – July 12, 2016** - HRA Pharma announced today the appointment of François Vuillet as Chief Executive Officer. Mr. Vuillet succeeds current CEO Erin Gainer, who becomes Non-Executive Director and an advisor to the company.

Mr. Thierry Timsit, Chairman of the HRA Pharma Board of Directors and general partner of Astorg, the company's largest investor stated, "Erin has been an exceptional leader during her 16-years career at HRA Pharma first as Research and Development Director then as CEO. She is credited with putting patient need at the center of the company's strategy, which has filled the company's portfolio with new, innovative products." Mr. Timsit continued, "We are confident that François will continue this track record of success. His proven operational experience and great relationship building skills make him a great fit to further develop the company's leading position."

"Having known and worked alongside François for a decade, I know that he is a great leader, passionate about our mission and committed to our values. He is the right leader to set the direction for the next phase of growth for our women's health and endocrinology franchises," said Erin Gainer, "I look forward to remaining actively engaged with HRA Pharma, and supporting François in his new role as CEO."

"The company will be forever grateful for Erin's long-sighted vision and leadership. She has left an incredible legacy and will continue to be an invaluable resource as a board member and advisor" said François Vuillet "I am honored to lead HRA Pharma into its next phase of growth, expanding the company's leadership position. Our objective is to become a leading specialty pharma continuing to reinvent healthcare for woman and rare diseases patients".

François Vuillet has near 15 years of operating and management experience within the Company. Immediately prior to becoming CEO of HRA Pharma, he served as Chief Operational Officer of the Company, a function within which he oversaw global corporate operations in over 80 countries worldwide. He earlier served as Head of Endocrinology then International Operations Director. In this role, he was instrumental in the inception of the Company's European footprint. He holds a Ph.D. in Pharmacy and a master from ESSEC Business School.

HRA Pharma is a leading European specialty pharma focused on women's health and endocrinology with a clear ambition for 2025, to be a trusted partner of patients and healthcare providers, providing an answer to their unmet medical needs. HRA Pharma 2025 strategy aims at reinforcing the company's European presence and building a strong women's health OTC franchise in the US while pursuing value creation through innovation.

**About HRA Pharma:**

*HRA Pharma is a privately-held European pharmaceutical company that designs products and targets therapeutic gaps in the areas of women's health and endocrinology, and uses innovative marketing solutions and socially-conscious programs to promote healthy management of drugs and diseases. Headquartered in Paris, France and with subsidiaries across Western Europe, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners that enables it to satisfy critical patient needs and improve patient health across the globe. Visit [www.hra-pharma.com](http://www.hra-pharma.com) for more information.*

**Press contact:**

Karina Bugnon - Communication coordinator

[k.bugnon@hra-pharma.com](mailto:k.bugnon@hra-pharma.com)

+33 (0)1 40 33 66 02